Nelfinavir: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Mohamed Moubarak (talk | contribs)
nocaptcha
3,170 edits
Ammu Susheela (talk | contribs)
nocaptcha, Administrators
14,466 edits
No edit summary
Line 1: Line 1:
__NOTOC__
<!--FDA-Labeled Indications and Dosage (Adult)-->
{{Nelfinavir}}
|fdaLIADAdult======Condition1=====
'''''For patient information, click <u>[[Nelfinavir (patient information)|here]]</u>'''''.


{{CMG}}
* Dosing Information


==Overview==
:* Dosage
'''Nelfinavir''' (brand name '''Viracept''') is an [[antiretroviral drug]] used in the treatment of the [[human immunodeficiency virus]] (HIV). Nelfinavir belongs to the class of drugs known as [[protease inhibitor (pharmacology)|protease inhibitors]] (PIs) and like other PIs is generally used in combination with other antiretroviral drugs.


Nelfinavir mesylate (Viracept, formally AG1343) is a potent and orally bioavailable human immunodeficiency virus [[HIV-1 protease]] inhibitor (Ki=2nM) and is widely prescribed in combination with [[HIV]] reverse transcriptase inhibitors for the treatment of HIV infection.<ref>{{cite journal |author=Zhang KE, Wu E, Patick AK, ''et al.'' |title=Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities |journal=Antimicrob. Agents Chemother. |volume=45 |issue=4 |pages=1086–93 |year=2001 |month=April |pmid=11257019 |pmc=90428 |doi=10.1128/AAC.45.4.1086-1093.2001 |url=}}</ref>
=====Condition2=====


==Category==
* Dosing Information
[[Protease inhibitor]]


==US Brand Names==
:* Dosage
VIRACEPT<sup>®</sup>


==FDA Package Insert==
=====Condition3=====


'''  [[Nelfinavir description|Description]]'''
* Dosing Information
'''| [[Nelfinavir clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Nelfinavir microbiology|Microbiology]]'''
'''| [[Nelfinavir indications and usage|Indications and Usage]]'''
'''| [[Nelfinavir contraindications|Contraindications]]'''
'''| [[Nelfinavir warnings and precautions|Warnings and Precautions]]'''
'''| [[Nelfinavir adverse reactions|Adverse Reactions]]'''
'''| [[Nelfinavir drug interactions|Drug Interactions]]'''
'''| [[Nelfinavir overdosage|Overdosage]]'''
'''| [[Nelfinavir dosage and administration|Dosage and Administration]]'''
'''| [[Nelfinavir how supplied|How Supplied]]'''
'''| [[Nelfinavir labels and packages|Labels and Packages]]'''


==Mechanism of Action==
:* Dosage
Nelfinavir is an inhibitor of the HIV-1 protease. Inhibition of the viral protease prevents cleavage of the gag and gag-pol polyprotein resulting in the production of immature, non-infectious virus.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = VIRACEPT (NELFINAVIR MESYLATE) TABLET, FILM COATED VIRACEPT (NELFINAVIR MESYLATE) POWDER [AGOURON PHARMACEUTICALS INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e72c2bc6-9462-4a2e-8e1d-b97592376cbd#nlm34089-3 | publisher =  | date =  | accessdate}}</ref>


==References==
=====Condition4=====
{{Reflist|2}}


[[Category:Antibiotics]]
* Dosing Information
[[Category:Wikinfect]]
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
|contraindications=* Condition1
 
<!--Warnings-->
|warnings=* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
 
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
|administration=* Oral
 
* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
|overdose====Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|mechAction=*
 
<!--Structure-->
|structure=*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
|howSupplied=*
|packLabel=<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
<!--Precautions with Alcohol-->
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title =  | url = }}</ref>
 
<!--Look-Alike Drug Names-->
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
 
<!--Drug Shortage Status-->
|drugShortage=
}}
{{PillImage
|fileName=No image.jpg
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
<!--Pill Image-->
 
 
 
<!--Label Display Image-->
 
 
 
 
 
<!--Category-->
 
[[Category:Drug]]

Revision as of 19:28, 12 February 2015

|fdaLIADAdult======Condition1=====

  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage


|offLabelAdultGuideSupport======Condition1=====

  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Nelfinavir in adult patients.

|offLabelAdultNoGuideSupport======Condition1=====

  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Nelfinavir in adult patients.


|fdaLIADPed======Condition1=====

  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Nelfinavir in pediatric patients.


|offLabelPedGuideSupport======Condition1=====

  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Nelfinavir in pediatric patients.

|offLabelPedNoGuideSupport======Condition1=====

  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Nelfinavir in pediatric patients.

|contraindications=* Condition1

|warnings=* Description

Precautions

  • Description


|clinicalTrials=There is limited information regarding Clinical Trial Experience of Nelfinavir in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

|postmarketing=There is limited information regarding Postmarketing Experience of Nelfinavir in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

|drugInteractions=* Drug

  • Description

|useInPregnancyFDA=* Pregnancy Category |useInPregnancyAUS=* Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Nelfinavir in women who are pregnant. |useInLaborDelivery=There is no FDA guidance on use of Nelfinavir during labor and delivery. |useInNursing=There is no FDA guidance on the use of Nelfinavir with respect to nursing mothers. |useInPed=There is no FDA guidance on the use of Nelfinavir with respect to pediatric patients. |useInGeri=There is no FDA guidance on the use of Nelfinavir with respect to geriatric patients. |useInGender=There is no FDA guidance on the use of Nelfinavir with respect to specific gender populations. |useInRace=There is no FDA guidance on the use of Nelfinavir with respect to specific racial populations. |useInRenalImpair=There is no FDA guidance on the use of Nelfinavir in patients with renal impairment. |useInHepaticImpair=There is no FDA guidance on the use of Nelfinavir in patients with hepatic impairment. |useInReproPotential=There is no FDA guidance on the use of Nelfinavir in women of reproductive potentials and males. |useInImmunocomp=There is no FDA guidance one the use of Nelfinavir in patients who are immunocompromised.

|administration=* Oral

  • Intravenous

|monitoring=There is limited information regarding Monitoring of Nelfinavir in the drug label.

  • Description

|IVCompat=There is limited information regarding IV Compatibility of Nelfinavir in the drug label.

|overdose====Acute Overdose===

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Nelfinavir in the drug label.


|drugBox= |mechAction=*

|structure=*

File:Nelfinavir01.png
This image is provided by the National Library of Medicine.

|PD=There is limited information regarding Pharmacodynamics of Nelfinavir in the drug label.

|PK=There is limited information regarding Pharmacokinetics of Nelfinavir in the drug label.

|nonClinToxic=There is limited information regarding Nonclinical Toxicology of Nelfinavir in the drug label.

|clinicalStudies=There is limited information regarding Clinical Studies of Nelfinavir in the drug label.

|howSupplied=* |packLabel= |fdaPatientInfo=There is limited information regarding Patient Counseling Information of Nelfinavir in the drug label.

|alcohol=* Alcohol-Nelfinavir interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

|brandNames=* ®[1]

|lookAlike=* A® — B®[2]

|drugShortage= }} {{#subobject: 

 |Page Name=Nelfinavir
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Nelfinavir
 |Label Name=Nelfinavir11.png

}}

{{#subobject: 

 |Label Page=Nelfinavir
 |Label Name=Nelfinavir11.png

}}

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)
Retrieved from "https://www.wikidoc.org/index.php?title=Nelfinavir&oldid=1067297"